Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Advertisement

Currently submitted to: JMIR Public Health and Surveillance

Date Submitted: Nov 1, 2020
Open Peer Review Period: Oct 30, 2020 - Dec 25, 2020
(currently open for review)

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Immunogenicity and Safety Profile of COVID-19 Vaccines- A Systematic Review

  • Reeju Maharjan; 
  • Aditya Bamboria; 
  • Neelam Asghar; 
  • Manish Shrestha; 
  • Syed W H Rizvi

ABSTRACT

Background:

An effective vaccine will be important in controlling severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic.

Objective:

In this study, we aim to analyze the degree of immunogenicity that rises after administering different vaccines, and to study their efficacy.

Methods:

We systematically reviewed multiple vaccine candidates at different stages of clinical trials to prevent Coronavirus disease in 2019 (COVID-19). We reviewed literature from four major electronic databases (PubMed, MEDLINE, PubMed Central, and Google scholar) to identify studies on SARS-CoV-2 vaccine candidates. This article included studies that include clinical trials in multiple stages and systematic reviews published in 2020. We performed a quality assessment with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for our articles.

Results:

We included a total of 19 articles. This review article has a total of 24,342 individuals. These studies show promising results regarding vaccines candidates, safety profiles, and immunogenicity with the effective generation of neutralizing antibodies and specific T-cell responses. Adverse effects range from mild to moderate, with no serious adverse effects reported. It is unclear how long the generated immunity will last, and a follow up of the study participants for an extended one-year period will be needed.

Conclusions:

Ascertaining vaccines' efficacy and safety in vulnerable populations is essential for the general use of vaccine use. A number of these vaccines are currently under phase III or to enter phase III and may increase vaccines' efficacy and safety in different populations.


 Citation

Please cite as:

Maharjan R, Bamboria A, Asghar N, Shrestha M, Rizvi SWH

Immunogenicity and Safety Profile of COVID-19 Vaccines- A Systematic Review

JMIR Preprints. 01/11/2020:25396

DOI: 10.2196/preprints.25396

URL: https://preprints.jmir.org/preprint/25396

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.